Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) Sort descending | Year Awarded |
---|---|---|---|---|---|---|---|---|
1R01DA056673-01
Show Summary |
Targeting Tiam1-Mediated Synaptic Plasticity for the Relief of Opioid Tolerance | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | Baylor College of Medicine | LI, LINGYONG (contact); TOLIAS, KIMBERLY | Houston, TX | 2022 |
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-031 Summary: Chronic opioid use results in tolerance, a primary driver for opioid misuse and overdose that directly contribute to increased morbidity and mortality. Changes in neuronal connectivity known as synaptic plasticity are a key determinant of opioid tolerance, but the underlying molecular mechanisms remain unclear. Tiam1 is a protein known to control the development of nerve cells and their connections and is also involved in morphine-induced neuronal changes. This research will examine Tiam1-mediated synaptic plasticity underlying opioid tolerance and validate Tiam1 as a potential therapeutic target for prevention of tolerance development. |
||||||||
1R61NS113316-01
Show Summary |
Discovery and analytical validation of Inflammatory bio-signatures of the human pain experience | Preclinical and Translational Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NINDS | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON | PROSSIN, ALAN RODNEY | Houston, TX | 2019 |
NOFO Title: Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-NS-18-041 Summary: Postoperative pain is a major contributor to the current opioid epidemic. Novel objective measures capable of personalizing pain care will enhance medical precision in prevention and treatment of postoperative pain. This project seeks to discover and validate a novel biosignature of the human pain experience, based on underlying IL-1 family cytokine activity and associated brain endogenous opioid function, that is readily quantifiable and clinically translatable to prevention and treatment of postoperative pain states. Specific aims will assess whether the novel biosignature will predict 1) experimentally induced pain during an experimental nociceptive pain challenge; 2) postoperative pain states with accuracy >75%, accounting for a wide range of variance in the human pain experience; and 3) postoperative pain states in an expanded clinically enriched sample. |
||||||||
1RF1NS113256-01
Show Summary |
Dnmt3a as an epigenetic target for chronic pain treatment | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | UNIVERSITY OF TX MD ANDERSON CAN CTR | PAN, ZHIZHONG Z | Houston, TX | 2019 |
NOFO Title: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-18-043 Summary: It is unclear what changes in the brain mediate the development of chronic pain from acute pain and how chronic pain may change responses to opioid reward for the altered liability of opioid abuse under chronic pain. Preliminary studies have found that Dnmt3a, a DNA methyltransferase that catalyzes DNA methylation for gene repression, is significantly downregulated in the brain in a time-dependent manner during the development of chronic pain and after repeated opioid treatment. This project will investigate whether Dnmt3a acts as a key protein in the brain for the development of chronic pain, and whether Dnmt3a could be a novel epigenetic target for the development of new drugs and therapeutic options for the treatment of chronic pain while decreasing abuse liability of opioids. |
||||||||
3R01NS111929-01A1S1
Show Summary |
Anatomic, Physiologic and Transcriptomic Mechanisms of Neuropathic Pain in Human DRG | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | UNIVERSITY OF TX MD ANDERSON CAN CTR | DOUGHERTY, PATRICK M | Houston, TX | 2020 |
NOFO Title: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome
NOFO Number: NOT-TR-20-008 Summary: Using neural tissues from pain patients, this project will investigate mechanisms of neuronal and/or immune dysfunction driving chronic pain. The researchers will use spatial transcriptomics on human dorsal root ganglion (DRG) and spinal cord tissues to examine the cellular expression profile for these targets using the 10X Genomics Visium technology. The use of tissues from control surgical patients and organ donors as well as surgical patients with neuropathic pain will enable validation of expression of these targets in human tissue as well as indication of their potential involvement in neuropathic pain. This collaborative effort will use DRGs removed from pain-phenotyped patients during neurological surgery, as well as lumbar DRGs and spinal cord from organ donors. This study will map the spatial transcriptomes at approximately single cell resolution in the human DRG and spinal cord. |
||||||||
1UG3NS127251-01A1
Show Summary |
Development of Pathology-Activated Drugs for Treatment of Neuropathic Pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | UNIVERSITY OF TX MD ANDERSON CAN CTR | GRACE, PETER M (contact); ABELL, ANDREW | Houston, TX | 2022 |
NOFO Title: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-21-010 Summary: The medication monomethyl fumarate, approved for treating multiple sclerosis, has pain-relieving properties, but it also has side effects that affect the digestive tract and decrease levels of white blood cells, a problem known as leukopenia. This project will limit the availability of monomethyl fumarate to areas in the central nervous system associated with pain. Targeting the delivery of this drug to pain-related regions may improve its safety profile for treating neuropathic pain. |
||||||||
1RF1NS113840-01
Show Summary |
Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | UNIVERSITY OF TX MD ANDERSON CAN CTR | GRACE, PETER MICHAEL | Houston, TX | 2019 |
NOFO Title: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-18-043 Summary: Effective treatments are elusive for the majority of patients with neuropathic pain. Reactive oxygen and nitrogen species (ROS/RNS) are involved in neuropathic pain, because they drive mitochondrial dysfunction, cytokine production, and neuronal hyperexcitability; therefore, stimulation of endogenous antioxidants is predicted to simultaneously resolve multiple neuropathic pain mechanisms. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that is a potential therapeutic target because it regulates the expression of a large number of endogenous antioxidant-related genes and can be activated with a single drug. This project will test the hypothesis that Nrf2 activation increases multiple endogenous antioxidants, therefore reversing neuropathic pain behaviors and counteracting neuropathic pain mechanisms that are driven by ROS/RNS and could provide an effective pain therapy, with minimal abuse/addictive potential. |
||||||||
1UC2AR082200-01
Show Summary |
Neuronal Anatomy, Connectivity, and Phenotypic Innervation of the Knee Joint | Preclinical and Translational Research in Pain Management | Restoring Joint Health and Function to Reduce Pain (RE-JOIN) | NIAMS | BAYLOR COLLEGE OF MEDICINE | LEE, BRENDAN (contact); ARENKIEL, BENJAMIN R; RAY, RUSSELL S; WYTHE, JOSHUA D | Houston, TX | 2022 |
NOFO Title: HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed)
NOFO Number: RFA-AR-22-009 Summary: Pain caused by degenerative joint diseases such as osteoarthritis (OA) is a major public health challenge that significantly affects quality of life for millions of Americans. There are no therapies available that offer pain relief and reverse the course of OA. This project will use state-of-the-art technologies to create a neuronal connectivity and molecular map of the mouse knee joint, which will help identify molecular signatures that can be targeted for therapy. The research will include animals of different ages and of both sexes and test joint effects after exercise, in animals with OA, and after gene therapy that delivers an experimental OA medication directly to the joint. |
||||||||
1R44NS115196-01
Show Summary |
A single dose long-acting non-addictive polymer conjugate formulation of buprenorphine that provides immediate and prolonged analgesia for post-operative pain | Cross-Cutting Research | Small Business Programs | NINDS | SERINA THERAPEUTICS, INC. | VIEGAS, TACEY XAVIER; MOREADITH, RANDALL W | Huntsville, AL | 2019 |
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-18-574 Summary: SER-227 is a long-acting polymer pro-drug of buprenorphine that is being developed to treat post- operative pain following major surgeries such as bunionectomy, abdominoplasty, thoracotomy and knee and hip surgery. The ultimate goal is to demonstrate that SER-227 can be manufactured and tested preclinically to show that it is safe for use in a Phase I clinical study. Aims include 1.SER-227 chemistry and process optimization to generate a technical package, 2. SER-227 manufactured under current Good Manufacturing Practices, 3. Evaluated in formal toxicology studies in rodent and non-rodent animals so that justifications can be made to support a ‘first-in-man’ study, and 4. Submission of an Investigational New Drug application (IND) along with a Phase I clinical protocol in normal volunteers to measure the safety, tolerability and pharmacokinetics of buprenorphine that is released from SER-227. |
||||||||
1R43HL167661-01A1
Show Summary |
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions | Cross-Cutting Research | Small Business Programs | NHLBI | OPALGENIX, INC. | PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR | Indianapolis, IN | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 |
||||||||
1R61DA059948-01
Show Summary |
Workforce and System Change to Treat Adolescent Opioid Use Disorder Within Integrated Pediatric Primary Care | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS | HULVERSHORN, LESLIE A (contact); AALSMA, MATTHEW; ADAMS, ZACHARY WILLIAM | Indianapolis, IN | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053 Summary: The overdose crisis has expanded rapidly among adolescent populations in recent years, largely due to illicit substances containing lethal amounts of the highly potent synthetic opioid fentanyl. However, a provider shortage limits access to effective treatment for adolescents with opioid use disorder and other substance use disorders (SUD). Although primary care is a promising setting for expanding delivery of SUD treatment to adolescents, many primary care providers lack the training, resources, and support systems to deliver these services confidently and effectively. This project will leverage a large-scale rollout of integrated behavioral health care in a statewide health system. The research will test whether embedding behavioral health specialists into primary care visits, introducing case management and electronic clinical decision support tools, and reducing stigma will increase delivery of SUD treatment to adolescents. |
||||||||
1UG3DA050923-01
Show Summary |
AMPA Antagonism: A Novel Pharmacology for Launching Recovery from Opioid Addiction | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS | Chambers, Robert | Indianapolis, IN | 2020 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: RFA-DA-19-002 Summary: The excruciating multiday experience of opioid withdrawal syndrome (OWS), is exacerbated by the opioid antagonist drugs naloxone and naltrexone. This industry-academia collaboration will explore the potential of the glutamate AMPA receptor antagonist Tezampanel (TZP). Animal studies have shown reduced hyperactivity in brain circuits involved in OWS, without relying on direct stimulation or antagonism of the opioid system ,and has already been delivered to over 500 human subjects and found to be safe for a potential migraine indication. This proposal will build up the evidence needed to apply for and conduct open label and blinded placebo-controlled human trials of TZP safety and efficacy for OWS. If successful, this project will allow planning for a pivotal registration trial for TZP for OWS, and as a transitional treatment to long-term recovery on naltrexone and help us stem the tide of the opioid crisis. |
||||||||
1R01HD096800-01
Show Summary |
EFFECTS OF OPIOID USE DISORDER IN PREGNANCY ON LONG-TERM MATERNAL AND CHILD OUTCOMES | Enhanced Outcomes for Infants and Children Exposed to Opioids | NICHD | Indiana University - Purdue University Indianapolis | SADHASIVAM, SENTHILKUMAR | Indianapolis, IN | 2018 | |
NOFO Title: Opioid Use Disorder in Pregnancy (R01)
NOFO Number: RFA-HD-18-036 Summary: Neonatal abstinence syndrome (NAS) rates have increased since 2000. To determine multifactorial genetic, psychosocial predictors of opioid-related maternal and infant outcomes using rigorous prospective longitudinal design, innovative combinatorial pharmacogenetic approach, fetal MRI, and neonatal brain resting state functional MRI analysis, we hypothesize that a combination of maternal and infant genetic profiles, maternal psychosocial factors, maternal opioid treatment response, fetal and neonatal neurodevelopment, and NAS treatment will affect maternal and childhood outcomes with prenatal opioid exposure. The specific aims are to (1) Identify high-risk genetic profiles and psychosocial factors in pregnant women with opioid use disorder (OUD) and predisposing to poor maternal opioid maintenance treatment outcomes; (2) Determine maternal-infant genetic profiles and maternal opioid treatment factors predicting adverse fetal development, severity of NAS, and neonatal brain function; and (3) Develop predictive models for maternal opioid relapse and poor long-term neurodevelopmental outcomes in children with in utero opioid exposure. |
||||||||
1R61NR020845-01
Show Summary |
Equity Using Interventions for Pain and Depression (EQUIPD) | Clinical Research in Pain Management | Advancing Health Equity in Pain Management | NINR | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS | MATTHIAS, MARIANNE | Indianapolis, IN | 2022 |
NOFO Title: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
NOFO Number: RFA-NS-22-037 Summary: Opioid overdose deaths disproportionately affect Black individuals in the United States. While the use of complementary and integrative pain treatments is effective and widely recommended, Black pain patients (especially those who also have depression) face barriers to the use of these approaches. This project will refine, test, and prepare to implement a novel approach to overcoming these treatment barriers. The research will partner with and empower Black patients to find safe, effective pain treatments that best match their values, preferences, and lifestyles. |
||||||||
3R01MD008931-05S1
Show Summary |
VIRTUAL PERSPECTIVE-TAKING TO REDUCE RACE AND SES DISPARITIES IN PAIN CARE | Clinical Research in Pain Management | NIMHD | Indiana University - Purdue University Indianapolis | HIRSH, ADAM T | Indianapolis, IN | 2018 | |
NOFO Title: NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (R01)
NOFO Number: RFA-MD-13-006 Summary: Previous studies found that African American (AA) and low socioeconomic status (SES) patients are less likely to receive guideline-concordant pain care relative to White and high SES patients. According to research and theory, enhancing clinician perspective-taking is a promising strategy for improving the care of AA and low SES patients. We have developed an innovative methodology that utilizes computer-simulated patients and environments to assess, understand, and remediate pain treatment disparities. Our approach allows for the intervention to be individually tailored to each trainee, thereby enhancing its impact. It also allows for individual trainees to gain exposure to a greater range of racially and socioeconomically diverse patients than can normally be obtained in traditional training settings. We hypothesize that our perspective-taking intervention will increase trainees’ knowledge of their own biases, enhance trainees’ empathy toward patients, and reduce trainees’ anxiety/threat toward patients, and that these changes will reduce pain treatment disparities. |
||||||||
1R01DA059321-01
Show Summary |
Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder | Enhanced Outcomes for Infants and Children Exposed to Opioids | The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development | NIDA | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS | RADHAKRISHNAN, RUPA | Indianapolis, IN | 2023 |
NOFO Title: HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-HD-23-035 Summary: Opioid use during pregnancy is associated with significant harmful health outcomes for infants including preterm birth, neonatal opioid withdrawal syndrome, and impaired brain-related problems. This project will combine advanced imaging of the fetal brain and placenta, genetics, and tissue and blood samples from the placenta to determine how opioid use during pregnancy affects development of the fetal brain and placenta. This research will provide novel and early molecular indicators (biomarkers) to as well as identify new strategies for diagnosing, treating, and preventing opioid harm to the fetus and mother. |
||||||||
1R61DA057660-01
Show Summary |
Fatal Overdose Review Teams – Research to Enhance Surveillance Systems (FORTRESS) | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS | AALSMA, MATTHEW (contact); RAY, BRADLEY ; REDA, KHAIRI | Indianapolis, IN | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 Summary: Overdose fatality review teams review cases of overdose deaths to identify system gaps and innovative prevention and intervention strategies. With the rise in overdose deaths, these multidisciplinary teams require more timely population-level data to inform their recommendations. This project will develop the Overdose Touchpoints Dashboard that uses real-time data and records from multiple sources to help visualize common “overdose touchpoints” for harm reduction services and treatment opportunities. This research will compare use of the dashboard to standard overdose fatality review practices. The project will assess multiple aspects related to use of the dashboard, including process, staff attitudes, implementation successes, and usability. |
||||||||
R41DA055405-01
Show Summary |
Virtual Reality Facilitation of Recovery from Opioid Use Disorder | Cross-Cutting Research | Small Business Programs | NIDA | Relate XR LLC | OBERLIN, BRANDON G (contact); NELSON, ANDREW | Indianapolis, IN | 2022 |
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-020 Summary: Relapse is common in people with opioid use disorder, and recovery attempts often fail within 6 months. This research project will test a novel virtual reality intervention to improve recovery outcomes for people recovering from opioid use disorder. By increasing future orientation and delay-of-reward behavior with a precision medicine personalized experience, the intervention is designed to enhance advantageous decision-making and increase positive future outcomes. The results of this study will provide critical data for creating a commercially viable software product for facilitating relapse prevention and improving opioid use disorder recovery outcomes. |
||||||||
1UG1HD107653-01
Show Summary |
Incorporating nonpharmacologic approaches into a comparative effectiveness pharmacologic trial for neonates with neonatal opioid withdrawal syndrome (NOWS) | Enhanced Outcomes for Infants and Children Exposed to Opioids | Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) | NICHD | INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS (IN) | SOKOL, GREGORY M | Indianapolis, IN | 2021 |
NOFO Title: HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial - Clinical Sites (UG1 Clinical Trial Required)
NOFO Number: RFA-HD-21-031 Summary: Neonatal Opioid Withdrawal Syndrome (NOWS) is a condition that occurs when newborns are exposed to opioids during pregnancy. Symptoms often include tremors, excessive crying, sleep deprivation, and swallowing difficulties. Cases are rising, with a newborn affected by NOWS approximately every 15 minutes. Currently, healthcare providers in the United States lack standard, evidence-based treatments for NOWS. |
||||||||
1R21NS130417-01
Show Summary |
The Role of Lysosomal Mechano-Sensitive Ion Channel in Pain | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | INDIANA UNIVERSITY PURDUE AT INDIANAPOLIS | TAN, ZHIYONG | Indianapolis, IN | 2022 |
NOFO Title: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
NOFO Number: TR22-011 Summary: Chronic pain severely reduces the quality of life and ability to work for millions of Americans. Because misuse of opioids for chronic pain treatment contributes to opioid addiction and opioid overdose, there is an urgent need to study novel non-opioid mechanisms, targets, and treatment strategies for chronic pain. Many ion channels control the flow of electrical signals in peripheral sensory neurons and are thus key targets for understanding and treating chronic pain. This project will conduct detailed studies to identify major ion channel-related molecular activities, targets, and treatment strategies for chronic pain. In particular, this research will explore the role of a specific ion channel (lysosomal mechanosensitive ion channel, orTmem63A) in neuropathic pain resulting from nerve injury. |
||||||||
3U24NS112873-04S3
Show Summary |
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NINDS | UNIVERSITY OF IOWA | SLUKA, KATHLEEN A (contact); COFFEY, CHRISTOPHER S; FREY LAW, LAURA A | Iowa City, IA | 2022 |
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-22-066 Summary: This research aims to define factors involved in the transition from acute to chronic pain, toward reducing opioid use and discovering new, non-addictive pain treatments. This project will develop recruitment efforts to engage a diverse patient population in clinical research that results from new findings about the transition from acute to chronic pain. The project will use focus groups, led by experts in health equity and implementation research, and patient navigators to enhance recruitment of diverse research participants. |
||||||||
1RF1NS113839-01
Show Summary |
Target validation of a novel CGRP receptor in migraine | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | UNIVERSITY OF IOWA | RUSSO, ANDREW F | Iowa City, IA | 2019 |
NOFO Title: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-18-043 Summary: Migraine is a painful and debilitating neurological condition, the development and maintenance of which involves the neuropeptide calcitonin gene-related peptide (CGRP). An exciting development in the treatment of migraine is the recent FDA approval of a new class of CGRP-targeted therapies designed to prevent migraine. However, these drugs meet a clinically relevant endpoint for only about half of the patients. This project will test the hypothesis that the high-affinity CGRP receptor AMY1 is a novel and unexplored target that mediates specific migraine-related behaviors in the brain and/or periphery to cause migraine. Validation of CGRP and AMY1 receptor involvement in migraines will create a new direction for the development of novel drugs and provide alternatives to opioids for management of migraine and potentially for other chronic pain conditions. |
||||||||
3U24NS112873-04S1
Show Summary |
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NINDS | UNIVERSITY OF IOWA | SLUKA, KATHLEEN A (contact); COFFEY, CHRISTOPHER S; FREY LAW, LAURA A | Iowa City, IA | 2022 |
NOFO Title: Clinical Coordination Center for Common Fund Acute to Chronic Pain Signatures (A2CPS) Program (U24 Clinical Trial Optional)
NOFO Number: RFA-RM-18-035 Summary: The Acute to Chronic Pain Signatures Program is developing a comprehensive data set that can be used to help predict which patients will recover from acute pain associated with surgery or injury and which ones will develop long-lasting chronic pain. This project will support an early career faculty member from a group underrepresented in biomedicine. The research will enhance skills development toward conducting and coordinating clinical pain research, generating omics datasets, advancing understanding of statistical methods, and other activities required for career development. |
||||||||
3R01NR015642-04S1
Show Summary |
SEVERE PAIN DURING WOUND CARE PROCEDURES: MODEL AND MECHANISMS | Clinical Research in Pain Management | NINR | University of Iowa | GARDNER, SUE E | Iowa City, IA | 2018 | |
NOFO Title: Chronic Wounds: Advancing the Science from Prevention to Healing (R01)
NOFO Number: RFA-NR-15-001 Summary: Wound care procedures (WCPs), such as dressing changes, cause moderate to severe pain in 74% of patients, nearly half of whom experience severe pain. Mainstay recommendations to prevent pain during WCPs have focused on either administration of preventive and procedural analgesia or use of expensive, non-adherent dressings. However, it is unclear which patients to target for analgesia or expensive dressings, leading to their inappropriate over- or underuse. To achieve the aims of the study, a comprehensive set of wound, patient, and biological factors will be measured concurrently with pain during a dressing change among a sample of 450 inpatients with open wounds. A predictive model will be developed and biological mechanisms will be examined using logistic regression. The proposed study has the potential to make significant contributions because clinicians will be able to target those patients requiring preventive pain control, thereby eliminating the spiraling impact of painful procedures on nociceptor sensitization. |
||||||||
1UG3AR076387-01
Show Summary |
Fibromyalgia TENS in Physical Therapy Study (TIPS): An embedded pragmatic clinical trial | Clinical Research in Pain Management | Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) | NIAMS | UNIVERSITY OF IOWA | SLUKA, KATHLEEN A (contact); CROFFORD, LESLIE J | Iowa City, IA | 2019 |
NOFO Title: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM)(UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-AT-19-004 Summary: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain, tenderness, and stiffness associated with fatigue and sleep disturbance. The investigators have recently completed a trial that demonstrated efficacy of active transcutaneous electrical nerve stimulation (TENS) compared with placebo TENS or no treatment in women with FM. While physical therapists are trained in using TENS, it is underused in clinical practice. This application proposes a pragmatic clinical trial of TENS for patients with FM to determine if the addition of TENS to physical therapy (PT) reduces pain, increases PT adherence, and helps achieve functional goals with less drug use. This study will address the critical need for strategies to implement effective nonpharmacologic treatments for FM. Successful completion of this trial will provide generalizable effectiveness data for referring providers, physical therapists, and insurers and will inform future pragmatic trials of nonpharmacologic treatments conducted in PT practices. |
||||||||
3UH3AR076387-02S1
Show Summary |
Fibromyalgia TENS in Physical Therapy Study (TIPS): An Embedded Pragmatic Clinical Trial: Administrative Supplement | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | UNIVERSITY OF IOWA | SLUKA, KATHLEEN A; CROFFORD, LESLIE J | Iowa City, IA | 2022 |
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain (Admin Supp – Clinical Trial Not Allowed)
NOFO Number: NOT-NS-22-087 Summary: This research is using a pragmatic clinical trial to test transcutaneous electrical nerve stimulation in patients with widespread muscle pain and tenderness (fibromyalgia). The research will determine if the addition of TENS to physical therapy reduces pain, increases physical therapy adherence, and helps achieve functional goals with less medication use. This project will involve early career scientists who will gain access to pragmatic research tools as well as develop the skills needed to pursue a career in clinical pain research focused on fibromyalgia. |